Pfizer signs $5.3 billion U.S. deal to supply COVID-19 antiviral pills
November 18, 2021; 10:21 AM EST
(Reuters) – Pfizer Inc (PFE.N) said on Thursday the U.S. government would pay $5.29 billion for 10 million courses of its experimental COVID-19 antiviral drug, as the country rushes to secure promising oral treatments for the disease.
The deal is roughly twice the size of the contract the U.S. government has with Merck & Co Inc (MRK.N), although the price for the Pfizer pill is lower at roughly $530 per course compared with about $700 for Merck’s.
Pfizer applied for emergency authorization of the drug, branded as Paxlovid, this week after reporting data showing that it was 89% effective at preventing hospitalization or death in at-risk people. read more
“While this pill still requires a full review by the Food and Drug Administration, I have taken immediate steps to secure enough supply for the American people,” President Joe Biden said in a statement. He added that his administration was making preparations to ensure the treatment is easily accessible and free.
Pfizer said it would begin deliveries of the treatment as soon as this year if it is authorized by the U.S. FDA.
Shares of Pfizer rose 1% to $51.40 in early trading, while those of Merck were marginally lower.
Getting vaccinated should still be the priority for Americans but having pills that can keep people out of the hospital “could be a lifesaver”, said the Department of Health and Human Services Secretary Xavier Becerra.
Pfizer has said it expects to manufacture 180,000 treatment courses by the end of next month and at least 50 million courses by the end of 2022.
Countries have scrambled to secure doses of the Pfizer and Merck oral drugs, based on promising data reported by both companies.
The U.S. government has so far secured 3.1 million courses of Merck’s COVID-19 pill for $2.2 billion, with the right to buy 2 million more courses in the future. read more
Our Standards: The Thomson Reuters Trust Principles.